{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T19:08:50Z","timestamp":1767121730163,"version":"3.48.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012431","name":"Jiangsu Provincial Agricultural Science and Technology Independent Innovation Fund","doi-asserted-by":"publisher","award":["BR2022068"],"award-info":[{"award-number":["BR2022068"]}],"id":[{"id":"10.13039\/501100012431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018529","name":"Major Project of Philosophy and Social Science Research in Colleges and Universities of Jiangsu Province","doi-asserted-by":"publisher","award":["22JZB002"],"award-info":[{"award-number":["22JZB002"]}],"id":[{"id":"10.13039\/501100018529","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Philosophy and Social Science Research Project of Jiangsu Higher Education Institutions","award":["2021SJA0075"],"award-info":[{"award-number":["2021SJA0075"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Public health emergencies such as COVID-19 severely disrupt drug supply chains, creating sudden surges in demand, labor shortages, and regulatory challenges. Existing studies often focus on single supply chain stages, with limited systematic analysis of policy responses across the entire cycle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aims to systematically analyze\u00a0China's\u00a0emergency drug supply policies by examining issuing agencies, developmental stages, policy tools, and supply chain links, to identify patterns, complementarities, and existing gaps.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 559 policy texts (110 national, 449 provincial) issued between December 2019 and February 2023 were collected. Content analysis and coding were conducted based on a four-dimensional framework. Social network analysis was applied to joint policy issuances to assess institutional collaboration and centrality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>National policies emphasized macro-level planning and dynamic adjustment: motivation and symbolic tools dominated in the burst stage, commands and regulations in the remission stage, and symbolic tools in later stages. Provincial policies relied more on rigid enforcement through commands and regulations, gradually shifting toward capacity-building in distribution and use. Finance, healthcare security, and regulatory agencies emerged as network hubs, while the distribution stage received the most policy support. Raw material supply was largely overlooked.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>National and provincial policies demonstrated complementary functions\u2014national policies providing strategic direction and provincial policies ensuring operational enforcement. However, imbalances in policy tool use, weak shortage monitoring, and insufficient human resource policies remain. Future research should incorporate municipal-level measures, field-based evaluations, and international comparisons to optimize\u00a0China's\u00a0emergency drug supply governance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0337700","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T19:05:35Z","timestamp":1767121535000},"page":"e0337700","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["The practice of drug emergency supply in China during the COVID-19 pandemic: A policy mix perspective"],"prefix":"10.1371","volume":"20","author":[{"given":"Zhang","family":"Jie-ying","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Jun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Xue-ya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Rui-xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Jun-lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2105-3921","authenticated-orcid":true,"given":"Mao","family":"Ning-ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"pone.0337700.ref001","doi-asserted-by":"crossref","first-page":"1092375","DOI":"10.3389\/fpubh.2022.1092375","article-title":"Establishment of the emergency material reserve mechanism for public health emergencies and optimization of the management of various functional departments","volume":"10","author":"Y Sun","year":"2023","journal-title":"Front Public Health"},{"issue":"3","key":"pone.0337700.ref002","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bpa.2020.11.007","article-title":"Principles of supply chain management in the time of crisis","volume":"35","author":"CN Okeagu","year":"2021","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"pone.0337700.ref003","unstructured":"National Bureau of Economic Research. The impacts of COVID-19 illnesses on workers. NBER Working Paper No. 30435. 2022. Available from: https:\/\/www.nber.org\/system\/files\/working_papers\/w30435\/w30435.pdf"},{"key":"pone.0337700.ref004","article-title":"Impact assessment of regulatory governance and regulatory policies on port sustainability performance","author":"M Roy","year":"2021","journal-title":"Singapore: Nanyang Technological University"},{"issue":"1","key":"pone.0337700.ref005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5582\/bst.2020.01043","article-title":"Challenges to the system of reserve medical supplies for public health emergencies: reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in China","volume":"14","author":"X Wang","year":"2020","journal-title":"Biosci Trends"},{"issue":"7","key":"pone.0337700.ref006","article-title":"Coping with drug shortages: a study of government-enterprise option cooperation stockpiling strategies for drugs in shortage considering API surrogate stockpiling subsidies","volume":"19","author":"Y Lan","year":"2024","journal-title":"PLoS One"},{"key":"pone.0337700.ref007","first-page":"100129","article-title":"Minimizing COVID-19 disruption: ensuring the supply of essential health products for health emergencies and routine health services","volume":"6","author":"A Lal","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"10","key":"pone.0337700.ref008","first-page":"1489","article-title":"Drug-dispensing limits within Medicaid during the COVID-19 pandemic","volume":"27","author":"JD Alpern","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"pone.0337700.ref009","doi-asserted-by":"crossref","first-page":"105030","DOI":"10.1016\/j.healthpol.2024.105030","article-title":"Tackling medicine shortages during and after the COVID-19 pandemic: compilation of governmental policy measures and developments in 38 countries","volume":"143","author":"S Vogler","year":"2024","journal-title":"Health Policy"},{"issue":"1","key":"pone.0337700.ref010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12889-024-21180-7","article-title":"Quantitative evaluation of China\u2019s public health emergencies response policies: a PMC index model approach","volume":"25","author":"Y Liu","year":"2025","journal-title":"BMC Public Health"},{"issue":"9","key":"pone.0337700.ref011","article-title":"Dynamic evolution of policy mix in response to COVID-19: Practice from China","volume":"18","author":"L Du","year":"2023","journal-title":"PLoS One"},{"key":"pone.0337700.ref012","first-page":"15","volume-title":"Crisis management: planning for the invisible","author":"S Fink","year":"2011"},{"key":"pone.0337700.ref013","unstructured":"The State Council of the People\u2019s Republic of China. Guiding opinions on doing a good job in the normalized prevention and control of the epidemic situation of new coronavirus pneumonia. 2020. Available from: http:\/\/www.gov.cn\/zhengce\/content\/2020-05\/08\/content_5509896.htm"},{"key":"pone.0337700.ref014","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2307\/2131904","article-title":"Behavioral assumptions of policy tools","volume":"52","author":"A Schneider","year":"1990","journal-title":"J Pol"},{"issue":"2","key":"pone.0337700.ref015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3102\/01623737009002133","article-title":"Getting the job done: alternative policy instruments","volume":"9","author":"LM McDonnell","year":"1987","journal-title":"Educ Eval Policy Anal"},{"key":"pone.0337700.ref016","unstructured":"Pharmanews Intelligence. Fundamentals of the pharmaceutical supply chain. 2023. Available from: https:\/\/pharmanewsintel.com\/news\/fundamentals-of-the-pharmaceutical-supply-chain"},{"key":"pone.0337700.ref017","unstructured":"China CDC. COVID-19 clinical and surveillance data\u2014December 9, 2022 to January 23, 2023, China. Chinese Center for Disease Control and Prevention. 2023. Available from: https:\/\/weekly.chinacdc.cn\/fileCCDCW\/cms\/news\/info\/upload\/13642969-aea5-40f9-aa10-165df32c50c0.pdf"},{"key":"pone.0337700.ref018","unstructured":"China State Statistical Bureau. Geography and climate\u2014ChinaFacts: regional divisions: Northeast, North, East, Central, South, Southwest, Northwest. Available from: https:\/\/www.hwwilsoninprint.com\/pdf\/ChinaFacts_pgs.pdf"},{"issue":"3","key":"pone.0337700.ref019","first-page":"243","article-title":"Real-world evidence in the United States: progress and future directions","volume":"7","author":"Y Zhang","year":"2018","journal-title":"J Comp Effect Res"},{"key":"pone.0337700.ref020","unstructured":"Guangdong Provincial Healthcare Security Administration. Notice on further strengthening the procurement and price monitoring of epidemic-related drugs and consumables. 2022. Available from: https:\/\/hsa.gd.gov.cn\/gkmlpt\/content\/4\/4070\/post_4070210.html#465"},{"key":"pone.0337700.ref021","unstructured":"FDA, CDER. Work to protect public health during the COVID-19 public health emergency. [cited 2023 Apr 24] Available from: https:\/\/www.fda.gov\/drugs\/coronavirus-covid-19-drugs\/cders-work-protect-public-health-during-covid-19-public-health-emergencyensure"},{"key":"pone.0337700.ref022","unstructured":"U.S. Food & Drug Administration. Coronavirus (COVID-19) | Drugs. 2021. [cited 2023 Apr 24] Available from: https:\/\/www.fda.gov\/drugs\/coronavirus-covid-19-drugs\/cders-work-protect-public-health-during-covid-19-public-health-emergencyensure"},{"key":"pone.0337700.ref023","unstructured":"Jilin Provincial Human Resources and Social Security Department. Notice on several policy measures to fully support the fight against the COVID-19 epidemic. 2022. Available from: https:\/\/hrss.jl.gov.cn\/gg\/202204\/t20220406_8430355.html"},{"key":"pone.0337700.ref024","unstructured":"China Council for the Promotion of International Trade, Zhejiang Provincial Committee. \u201cLabor shortage\u201d sweeps major industrial countries! Is a global \u201ctalent scramble\u201d about to begin? 2021. Available from: http:\/\/www.ccpitzj.gov.cn\/art\/2021\/11\/24\/art_1229557691_21290.html"},{"issue":"6","key":"pone.0337700.ref025","doi-asserted-by":"crossref","DOI":"10.1017\/dmp.2020.299","article-title":"Internet public opinion evolution in the COVID-19 event and coping strategies","volume":"15","author":"Z Zhong","year":"2021","journal-title":"Disaster Med Public Health Prep"},{"key":"pone.0337700.ref026","unstructured":"FDA. Coronavirus update: FDA and FTC warn seven companies selling fraudulent products that claim to treat or prevent COVID-19. 2020. [cited 2023 Apr 24] Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-update-fda-and-ftc-warn-seven-companies-selling-fraudulent-products-claim-treat-or"},{"key":"pone.0337700.ref027","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3390\/v12040372","article-title":"Virology, epidemiology, pathogenesis, and control of COVID-19","volume":"12","author":"Y Jin","year":"2020","journal-title":"Viruses"},{"issue":"8","key":"pone.0337700.ref028","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3390\/healthcare10081594","article-title":"Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?","volume":"10","author":"D Horgan","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"pone.0337700.ref029","unstructured":"Information Office of the State Council of the People\u2019s Republic of China. China action to fight the epidemic of new coronary pneumonia. 2020. Available from: http:\/\/www.gov.cn\/zhengce\/2020-06\/07\/content_5517737.html"},{"issue":"1","key":"pone.0337700.ref030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12998\/wjcc.v10.i1.1","article-title":"Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance","volume":"10","author":"S-Y Ren","year":"2022","journal-title":"World J Clin Cases"},{"key":"pone.0337700.ref031","doi-asserted-by":"crossref","first-page":"1125246","DOI":"10.3389\/fimmu.2023.1125246","article-title":"The development of COVID-19 treatment","volume":"14","author":"Y Yuan","year":"2023","journal-title":"Front Immunol"},{"key":"pone.0337700.ref032","article-title":"The practice of drug emergency supply in China from a policy mix perspective","author":"J Zhang","year":"2024","journal-title":"Res Square"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0337700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T19:05:43Z","timestamp":1767121543000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0337700"}},"subtitle":[],"editor":[{"given":"John G.","family":"Rizk","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0337700","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}